CLINICAL ROLE -
Trilaciclib Protects Against Chemotherapy-Induced Myelosuppression
Treatment's approval marks exciting new development for patients with ES-SCLC to prevent CIM.
Read More
Help Manage Toxicities With BRAF and MEK Inhibitors
Watch for alopecia, arthralgia, diarrhea, fatigue, nausea, pyrexia, rash, and vomiting, among others.
FDA Approves Newest Antibody-Drug Conjugate for Cervical Cancer
Tisotumab vedotin-tftv is used as antitumor therapy for patients with disease progression during or after chemotherapy.
Calls Grow for Treatment Deintensification of HPV-Positive OPC
Clinicians cite long-term complications and younger patients with better prognoses as reasons to pull back on oropharyngeal cancer therapy.
Immunotherapy Revolutionizes Treatment of ES-SCLC
Addition of atezolizumab and durvalumab to chemotherapy is a win for patients with extensive-stage small cell lung cancer